share_log

藥明康德：有關完成第二次回購本公司A股及註銷本公司A股的公告

WUXI APPTEC: ANNOUNCEMENT ON THE COMPLETION OF THE REPURCHASEOF A SHARES OF THE COMPANY FOR THE SECOND TIME ANDCANCELLATION OF A SHARES OF THE COMPANY

HKEX ·  May 23 18:31

Summary by Futu AI

药明康德宣布完成第二次股份回購計劃，並將回購的A股全部註銷。該公司於2024年3月11日開始實施回購，至2024年5月22日完成，共回購A股21,593,780股，佔已發行總股本的0.74%，使用資金總額達人民幣1,000,000,116.95元。回購價格範圍為每股41.23元至58.66元。此次回購不會對公司經營、財務狀況及未來發展造成重大影響，也不會影響公司的上市地位。董事會成員包括執行董事李革博士等，並於2024年5月23日由董事長李革博士發出公告。
药明康德宣布完成第二次股份回購計劃，並將回購的A股全部註銷。該公司於2024年3月11日開始實施回購，至2024年5月22日完成，共回購A股21,593,780股，佔已發行總股本的0.74%，使用資金總額達人民幣1,000,000,116.95元。回購價格範圍為每股41.23元至58.66元。此次回購不會對公司經營、財務狀況及未來發展造成重大影響，也不會影響公司的上市地位。董事會成員包括執行董事李革博士等，並於2024年5月23日由董事長李革博士發出公告。
KAND PHARMACEUTICALS ANNOUNCED THE COMPLETION OF THE SECOND SHARE REPURCHASE PROGRAM AND THE WRITE-DOWN OF ALL OF THE REPURCHASED A SHARES. The Company began repurchasing on March 11, 2024 and completed by May 22, 2024. A total of 21,593,780 shares of A shares representing 0.74% of the total issued share capital amounted to RMB1,000,000,116.95. The repurchase price ranges from $41.23 to $58.66 per share. The repurchase will not have a material impact on the Company's operations, financial condition and future development, nor will it affect the Company's listing position. The members of the Board of Directors include Dr. Li Keung, the Executive Director, etc., and an announcement was made on 23 May 2024 by the Chairman, Dr. Li Keung.
KAND PHARMACEUTICALS ANNOUNCED THE COMPLETION OF THE SECOND SHARE REPURCHASE PROGRAM AND THE WRITE-DOWN OF ALL OF THE REPURCHASED A SHARES. The Company began repurchasing on March 11, 2024 and completed by May 22, 2024. A total of 21,593,780 shares of A shares representing 0.74% of the total issued share capital amounted to RMB1,000,000,116.95. The repurchase price ranges from $41.23 to $58.66 per share. The repurchase will not have a material impact on the Company's operations, financial condition and future development, nor will it affect the Company's listing position. The members of the Board of Directors include Dr. Li Keung, the Executive Director, etc., and an announcement was made on 23 May 2024 by the Chairman, Dr. Li Keung.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated